Opus Genetics (IRD) Invested Capital (2021 - 2022)

Opus Genetics (IRD) posted quarterly Invested Capital of $215000.0 for Q1 2022, down 60.04% quarter-over-quarter from $538000.0 in Q4 2021.

Opus Genetics (IRD) Invested Capital (2021 - 2022) Analysis & Trends

Opus Genetics (IRD) has reported Invested Capital for 2 consecutive years, with $215000.0 the latest figure, recorded in Q1 2022.

  • In Q1 2022, Invested Capital changed N/A year-over-year to $215000.0; the TTM figure through Dec 2022 stood at $215000.0 (down 60.04% YoY), while the FY2021 annual figure was $538000.0, changed N/A from the prior year.
  • Invested Capital fell to $215000.0 in Q1 2022 per IRD's latest filing, from $538000.0 in the prior quarter.
  • Across five years, Invested Capital topped out at $538000.0 in Q4 2021 and bottomed at $215000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 190.90 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 2.57 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 380.00 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Opus Genetics 298.36 Mn 209.55 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2022 215,000.00
Dec 31, 2021 538,000.00